425: Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results and Merger Agreement with TuHURA Biosciences

Kintara Therapeutics reported its Q3 2024 financial results, highlighting a merger agreement with TuHURA Biosciences and progress in its REM-001 study.

Summary

• Kintara Therapeutics announced its financial results for the third quarter of fiscal year 2024, ended March 31, 2024.
• The company reported a net loss of approximately $2.0 million, or $0.05 per share, compared to a net loss of approximately $3.3 million, or $1.94 per share, for the three months ended March 31, 2023.
• As of March 31, 2024, Kintara had cash and cash equivalents of approximately $6.35 million.
• Kintara entered into a definitive merger agreement with TuHURA Biosciences, expected to close in the third quarter of 2024.
• Kintara's stockholders will receive contingent value rights (CVR) entitling them to shares of common stock upon achievement of enrollment of a minimum of 10 patients in the REM-001 study, with such patients each completing 8 weeks of follow-up on or before December 31, 2025.
• Post-merger, Kintara's stockholders are expected to own approximately 2.85%, or approximately 5.45% including the shares underlying the CVR if the milestone is achieved, of the common stock of the post-Merger combined company on a fully-diluted basis.
• The company is conducting an open-label 15-patient study in CMBC patients evaluating REM-001, with the majority of costs covered by a $2.0 million SBIR grant from the NIH.

Sentiment

Score: 6

Explanation: The announcement includes both positive developments (improved financial results, merger agreement) and negative aspects (dilution for existing shareholders, ongoing losses). The overall sentiment is neutral to slightly positive.

Positives

• The net loss decreased for the three months ended March 31, 2024, compared to the three months ended March 31, 2023.
• Kintara's cash position improved to $6.35 million as of March 31, 2024, compared to $1.535 million as of June 30, 2023.
• The company regained compliance with Nasdaq's minimum stockholders' equity requirement.
• The merger with TuHURA Biosciences could provide access to new technologies and growth opportunities.
• The REM-001 study is being partially funded by a $2.0 million grant, reducing the financial burden on the company.

Negatives

• Kintara reported a net loss of $2.0 million for the third quarter of fiscal year 2024.
• Existing Kintara stockholders will have their ownership significantly diluted post-merger, owning only approximately 2.85% of the combined company (or 5.45% if the CVR milestone is met).
• General and administrative costs increased due to professional fees related to the proposed transaction with TuHURA.

Risks

• The merger with TuHURA is subject to various closing conditions, including stockholder approval.
• Delays in closing the merger could impact the anticipated cash resources of the combined company.
• The combined company's ability to correctly estimate operating expenses and manage cash resources is uncertain.
• The success of the combined business of TuHURA and Kintara is not guaranteed.
• The company faces risks related to protecting its intellectual property rights and competitive responses to the merger.

Future Outlook

The company anticipates closing the merger with TuHURA Biosciences in the third quarter of 2024 and is focused on advancing the REM-001 study and TuHURA's IFx-2.0 product candidate.

Industry Context

Kintara's merger with TuHURA reflects a trend in the biopharmaceutical industry towards consolidation and strategic partnerships to enhance pipelines and address unmet medical needs in cancer therapy.

Comparison to Industry Standards

• Kintara's cash position of $6.35 million is relatively low compared to other publicly traded biopharmaceutical companies at a similar stage of development; for example, companies like Galera Therapeutics or Veru Inc. often maintain cash reserves in the tens of millions.
• The Q3 net loss of $2.0 million is within the typical range for small-cap biotech companies focused on clinical development, but the burn rate will need to be carefully managed post-merger.
• The REM-001 study, while promising, is still in early stages compared to Phase 3 trials being conducted by larger pharmaceutical companies like Merck (Keytruda) in similar cancer indications.
• TuHURA's IFx-2.0 personalized cancer vaccine candidate is competing in a crowded immuno-oncology space, where companies like BioNTech and Moderna are also developing mRNA-based cancer vaccines.

Stakeholder Impact

• Shareholders of Kintara will experience dilution upon completion of the merger, but also have the potential for future value through CVRs.
• Employees of both Kintara and TuHURA may experience uncertainty during the merger integration process.
• Patients with CMBC may benefit from the continued development of REM-001 therapy.
• The merger could create new opportunities for suppliers and partners of the combined company.

Next Steps

• Obtain stockholder approval for the proposed merger with TuHURA Biosciences.
• Close the merger transaction in the third quarter of 2024.
• Continue the open-label 15-patient study in CMBC patients evaluating REM-001.
• Advance the development of TuHURA's IFx-2.0 product candidate.

Key Dates